文献速递肝病

人工智能心电图在预测代谢功能障碍相关脂肪性肝病中的表现

Performance of AI-Enabled Electrocardiogram in the Prediction of Metabolic Dysfunction-Associated Steatotic Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-27

本研究为回顾性研究,纳入明尼苏达州奥姆斯特德县1996至2019年诊断的3468例MASLD患者和25407例对照,训练并验证基于卷积神经网络的AI心电图模型以识别MASLD。AI-ECG模型在原队列和验证队列的AUC分别为0.69和0.62,与使用单一临床参数的模型表现相当或更优,但不及联合临床参数的模型(AUC 0.76和0.72)。

要点

  • AI心电图模型预测MASLD的AUC在原队列为0.69,验证队列为0.62。
  • 联合ECG、年龄、性别、BMI、糖尿病和ALT的模型AUC最高,原队列0.76,验证队列0.72。
  • AI心电图模型表现与使用单一临床参数的模型相当或更优,但不优于联合临床参数模型。

核心结论

  • 概念验证研究提示,基于AI的心电图模型可检测MASLD,其表现与使用单一临床参数的模型相当或更优,但不优于联合临床参数的模型;心电图可作为非肝病领域的另一种MASLD筛查工具。

研究设计与样本

  • 回顾性研究,纳入明尼苏达州奥姆斯特德县1996至2019年诊断的成人MASLD患者及对照,病例和对照在研究入组前6年内及入组后1年内均有心电图检查。
  • 基于卷积神经网络的AI心电图模型按70%、10%、20%的比例分别进行训练、验证和测试,并在Mayo Clinic Enterprise的独立队列中进行外部验证。

主要发现

  • 共识别3468例MASLD病例和25407例对照。
  • AI-ECG模型预测MASLD的AUC在原队列为0.69,在验证队列为0.62。
  • AI-ECG模型表现与年龄和性别校正的BMI模型(AUC 0.71)、糖尿病或高血压或高脂血症模型(AUC 0.68)或仅糖尿病模型(AUC 0.66)相似或更优。
  • 联合ECG、年龄、性别、BMI、糖尿病和丙氨酸氨基转移酶的模型AUC最高,原队列为0.76,验证队列为0.72。

临床怎么用

  • 作者认为,心电图可作为非肝病领域的另一种MASLD筛查工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Accessible noninvasive screening tools for metabolic dysfunction-associated steatotic liver disease (MASLD) are needed. We aim to explore the performance of a deep learning-based artificial intelligence (AI) model in distinguishing the presence of MASLD using 12-lead electrocardiogram (ECG). METHODS: This is a retrospective study of adults diagnosed with MASLD in Olmsted County, Minnesota, between 1996 and 2019. Both cases and controls had ECGs performed within 6 years before and 1 year after study entry. An AI-based ECG model using a convolutional neural network was trained, validated, and tested in 70%, 10%, and 20% of the cohort, respectively. External validation was performed in an independent cohort from Mayo Clinic Enterprise. The primary outcome was the performance of ECG to identify MASLD, alone or when added to clinical parameters. RESULTS: A total of 3468 MASLD cases and 25,407 controls were identified. The AI-ECG model predicted the presence of MASLD with an area under the curve (AUC) of 0.69 (original cohort) and 0.62 (validation cohort). The performance was similar or superior to age- and sex-adjusted models using body mass index (AUC, 0.71), presence of diabetes, hypertension or hyperlipidemia (AUC, 0.68), or diabetes alone (AUC, 0.66). The model combining ECG, age, sex, body mass index, diabetes, and alanine aminotransferase had the highest AUC: 0.76 (original) and 0.72 (validation). CONCLUSIONS: This is a proof-of-concept study that an AI-based ECG model can detect MASLD with a comparable or superior performance as compared with the models using a single clinical parameter but not superior to the combination of clinical parameters. ECG can serve as another screening tool for MASLD in the nonhepatology space.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Udompap P, Liu K, Attia IZ, et al. Performance of AI-Enabled Electrocardiogram in the Prediction of Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2024. PMID: 39209186. doi:10.1016/j.cgh.2024.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。